KYNTRA BIO, INC. cotiza a 6.12 USD y tiene una capitalización bursátil de $25M. En los últimos 12 meses ha facturado $5M con un margen de flujo de caja libre del -74.7%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is a…
| Métrica | KYNB | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 91.4% | 57.0% | +34.3% |
| Operating Margin | -712.7% | -38.6% | -674.0% |
| Net Margin | 2848.6% | -33.6% | +2882.2% |
| FCF Margin | -74.7% | -13.9% | -60.9% |
| ROE | — | -40.4% | — |
| ROA | 153.4% | -32.0% | +185.4% |
| Current Ratio | 3.39 | 2.84 | +0.55 |
| Debt / Equity | — | 0.28 | — |